Antibody response to dengue virus

Cedillo‐Barrón, Leticia; García‐Cordero, Julio; Bustos-Arriaga, José; León-Juárez, Moisés; Gutiérrez-Castañeda, Benito

doi:10.1016/j.micinf.2014.07.011

Cited by 22 publications

(22 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The corresponding simplified metabolic network is represented in Figure Once the biomass reaches the target concentration (usually after several days), the bioreactor is infected at time of infection (TOI). The concentration of infectious virus Vir injected is such that the ratio Vir / X is equal to multiplicity of infection (MOI). Just after infection of the culture, virions start binding to the cell receptors and penetrate the biomass through endocytosis in order to get translated and replicated . It is assumed that the amount of substrates and metabolites respectively consumed and produced for virion production is significantly lower than the one related to biomass duplication and is therefore neglected. After several hours, the first replicated virions are released in the culture medium and the amplification stage begins.…”

Section: Model Descriptionmentioning

confidence: 99%

“…Just after infection of the culture, virions start binding to the cell receptors and penetrate the biomass through endocytosis in order to get translated and replicated. 11,12 It is assumed that the amount of substrates and metabolites respectively consumed and produced for virion production is significantly lower than the one related to biomass duplication and is therefore neglected. 4.…”

Section: Population Balance Modelmentioning

confidence: 99%

See 1 more Smart Citation

Variable selection and parameter estimation of viral amplification in vero cell cultures dedicated to the production of a dengue vaccine

Abbate

Dewasme

Wouwer

2018

Biotechnology Progress

View full text Add to dashboard Cite

In this study, a dynamic model of a Vero cell culture-based dengue vaccine production process is developed. The approach consists in describing the process dynamics as functions of the whole living (uninfected and infected) biomass whereas previous works are based on population balance approaches. Based on the assumption that infected biomass evolves faster than other variable, the model can be simplified using a slow-fast approximation. The structural identifiability of the model is analysed using differential algebra as implemented in the software DAISY. The model parameters are inferred from experimental datasets collected from an actual vaccine production process and the model predictive capability is confirmed both in direct and cross-validation. The model prediction shows the impact of the metabolism on virus yield and confirms observations reported in previous studies. Multi-modality and sensitivity analysis complement the parameter estimation, and allow to obtain confidence intervals on both parameters and state estimates. Finally, the model is used to compute the maximum infectious virus yield that can be obtained for different combinations of multiplicity of infection (MOI) and time of infection (TOI). © 2018 American Institute of Chemical Engineers Biotechnol. Prog., 2018.

show abstract

Section: Model Descriptionmentioning

confidence: 99%

Section: Population Balance Modelmentioning

confidence: 99%

Variable selection and parameter estimation of viral amplification in vero cell cultures dedicated to the production of a dengue vaccine

Abbate

Dewasme

Wouwer

2018

Biotechnology Progress

View full text Add to dashboard Cite

show abstract

“…26 It has three major proteins: capsid (C), premembrane (prM), and envelope (E) protein, with the E and prM proteins being the main targets of the humoral immune response. 27 The prM protein is involved in assembly of the viral RNA with E protein and association with membranes derived from the endoplasmic reticulum. The E protein undergoes conformational changes and promotes fusion with the endosomes after viral entry.…”

Section: Bnabs Against Dengue Virusmentioning

confidence: 99%

Broadly neutralizing antibodies for therapy of viral infections

Srinivasan¹,

Ghosh²,

Maity³

et al. 2016

ANTI

View full text Add to dashboard Cite

Neutralizing antibodies (NAbs) are an essential part of the human immune response that involves an intricate relationship between the innate and adaptive immune system to prevent infection. The appearance of NAbs is a hallmark of viral infection in patients with HIV, dengue, hepatitis C virus, Ebola, and influenza. These viruses are characterized by high genetic diversity of viral epitopes arising due to a high replication rate and an error-prone replication machinery. In general, almost all infected individuals develop strain-specific NAbs in a fairly short period of time. In contrast, broadly neutralizing antibodies (bNAbs) show subdominant responses and are found only in a subset of patients, typically after a lengthy period of infection. Epitopes targeted by specific NAbs and bNAbs evolved thereafter provide useful information for vaccine design. In this review, we discuss the isolation and utility of bNAbs against HIV-1, dengue, hepatitis C virus, influenza, and Ebola. Passive antibody therapy and the economics of NAb therapy are also discussed.

show abstract

“…The structural protein of the virus X The journal homepage www.jpacr.ub.ac.id p-ISSN : 2302 -4690 | e-ISSN : 2541 -0733 102 such as envelope (E) glycoprotein of the virus membranes is the most exposed structure as principal target of neutralizing antibodies and has affects host cell receptor binding [12], [13], [14]. The glycosylation of E protein pattern differs according to DENV serotype.…”

Section: Introductionmentioning

confidence: 99%

“…The degree and position of N-linked glycans affect the antigenic properties of DENV. The antigenic determinants of a number of biologically important substances consist of carbohydrates [15], [13]. E protein is the target for antigenic region to determined vaccine development today.…”

Section: Introductionmentioning

confidence: 99%

Polytope Prediction for Dengue Vaccine Candidate Based on Conserved Envelope Glycoprotein of Four Serotypes of Dengue Virus and Its Antigenicity

Himmah

Fitriyah

Ardyati

et al. 2016

J. Pure App. Chem. Res.

View full text Add to dashboard Cite

Dengue fever reported endemic in tropical and sub-tropical country. Dengue fever caused by dengue virus, has Envelope protein that often used for vaccine development to prevent the virus infection. Vaccine development to prevent four serotype dengue virus infection still unavailable. This study aims to design polytope from four conserved epitopes of dengue virus envelope glycoprotein to prevent infection of heterotypic dengue virus and predict its antigenic challenge by molecular docking. We investigate molecular modeling of polytope, immunoinformatics analysis of polytope, protein structure of antibodies, molecular docking and protein-protein docking assessment. The polytope categorized as a stabil protein with index 29.72, has molecular weight 6,139 kDa, has three exposed antigenic determinants region and has estimated half-life is: 3.5 hours (mammalian reticulocytes, in vitro),10 min (yeast, in vivo), and >10 hours (Escherichia coli, in vivo). The Polytope binds with four broadly neutralizing antibodies of B7, C8, A11, and C10 (bnAbs) which estimated that four bnAbs can recognize four serotypes of dengue virus. The designed polytope has prospect to produce in Escherichia coli and can be applied as vaccine of heterotypic dengue virus serotype. Polytope is potentially able to generate humoral and cellular immunity.

show abstract

Antibody response to dengue virus

Cited by 22 publications

References 94 publications

Variable selection and parameter estimation of viral amplification in vero cell cultures dedicated to the production of a dengue vaccine

Variable selection and parameter estimation of viral amplification in vero cell cultures dedicated to the production of a dengue vaccine

Broadly neutralizing antibodies for therapy of viral infections

Polytope Prediction for Dengue Vaccine Candidate Based on Conserved Envelope Glycoprotein of Four Serotypes of Dengue Virus and Its Antigenicity

Contact Info

Product

Resources

About